|
Genetic predisposition to MDS: diagnosis and management
|
Dec 2019
|
Hematology. American Society of Hematology. Education Program
|
myelodysplastic syndromes (MDS)
|
|
Monitoring and treatment of MDS in genetically susceptible persons
|
Dec 2019
|
Hematology. American Society of Hematology. Education Program
|
myelodysplastic syndromes (MDS)
|
|
Lowering the boom on lower-risk myelodysplastic syndromes
|
Dec 2019
|
Hematology. American Society of Hematology. Education Program
|
myelodysplastic syndromes (MDS)
|
|
Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study
|
Dec 2019
|
JAMA Oncology
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis
|
Dec 2019
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party
|
Dec 2019
|
Bone Marrow Transplantation
|
aplastic anemia
|
|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria
|
Dec 2019
|
Leukemia & Lymphoma
|
aplastic anemia
|
|
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
|
Jan 2020
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology
|
myelodysplastic syndromes (MDS)
|
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
|
Jan 2020
|
The New England Journal of Medicine
|
myelodysplastic syndromes (MDS)
|
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
|
Jan 2020
|
Haematologica
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
